ABP4 Antibody

What is ABCB4 and why is it important in research?

ABCB4 (also known as MDR3, MDR2, MDR2/3, ABC21, GBD1, and phosphatidylcholine translocator) is a 141.5 kDa protein belonging to the ATP-binding cassette transporter family. It plays a crucial role in phospholipid transport across the canalicular membrane of hepatocytes. ABCB4 dysfunction has been linked to various liver diseases, including progressive familial intrahepatic cholestasis type 3 (PFIC3), intrahepatic cholestasis of pregnancy, and drug-induced liver injury. Research on ABCB4 is important for understanding the molecular mechanisms of these conditions and developing potential therapeutic strategies .

How do I choose the most appropriate ABCB4 antibody for my research?

When selecting an ABCB4 antibody, consider the following factors:

• Experimental application: Different antibodies are optimized for specific applications such as Western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF), flow cytometry (FCM), or ELISA. Choose an antibody that has been validated for your intended application .

• Species reactivity: Ensure the antibody recognizes ABCB4 in your species of interest. Available antibodies react with human, mouse, rat, and other species as indicated in the product information .

• Epitope specificity: Antibodies targeting different regions (N-terminal, middle region, C-terminal) may yield different results. Consider whether your experiment requires detection of specific domains or if post-translational modifications might affect antibody binding .

• Conjugation requirements: Determine whether you need an unconjugated antibody or one conjugated to a specific tag (biotin, Cy3, DyLight488, etc.) based on your detection system .

• Validation evidence: Look for antibodies with published citations and verification data including Western blot images or immunohistochemistry results .

What are the differences between monoclonal and polyclonal ABCB4 antibodies?

Monoclonal and polyclonal ABCB4 antibodies offer distinct advantages depending on your research needs:

Monoclonal ABCB4 antibodies:

• Recognize a single epitope on the ABCB4 protein

• Provide high specificity and low background

• Ensure consistent lot-to-lot reproducibility

• Particularly useful for distinguishing between closely related proteins (e.g., ABCB1 vs. ABCB4)

• Ideal for applications requiring precise epitope targeting

• Examples include clones P3II-26 and EPR23697-35 shown in the search results

Polyclonal ABCB4 antibodies:

• Recognize multiple epitopes on the ABCB4 protein

• Offer higher sensitivity through signal amplification

• More tolerant to minor protein denaturation or modifications

• Better for detection of proteins expressed at low levels

• Useful for applications where protein conformation may vary

• Available from multiple suppliers with different host species options

What are the optimal conditions for Western blot detection of ABCB4?

For successful Western blot detection of ABCB4 (141.5 kDa), follow these methodology-specific recommendations:

Sample preparation:

• Extract total protein from tissues (liver is optimal) or cells using RIPA buffer containing protease inhibitors

• Include phosphatase inhibitors if studying phosphorylation states

• Avoid excessive heat during sample preparation as ABCB4 is a membrane protein susceptible to aggregation

Gel electrophoresis conditions:

• Use 7.5% or 4-12% gradient gels due to ABCB4's large molecular weight

• Load 25-50 μg of total protein per lane

• Include positive control samples (e.g., liver tissue lysate)

Transfer parameters:

• Perform wet transfer at 30V overnight at 4°C for optimal transfer of this large protein

• Use PVDF membrane rather than nitrocellulose for better protein retention

Blocking and antibody incubation:

• Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Dilute primary antibody according to manufacturer's recommendation (typically 1:500-1:2000)

• Incubate with primary antibody overnight at 4°C

• Use secondary antibody at 1:5000-1:10000 dilution

Detection considerations:

• Enhanced chemiluminescence (ECL) detection systems work well

• Longer exposure times may be necessary to visualize bands clearly

• Expect the main band at approximately 140-150 kDa

How can I optimize immunohistochemistry protocols for ABCB4 detection in tissue samples?

For optimal ABCB4 detection in tissue sections by immunohistochemistry:

Tissue preparation:

• Use freshly fixed (10% neutral buffered formalin for 24-48 hours) and paraffin-embedded tissues

• For frozen sections, snap-freeze tissues in optimal cutting temperature (OCT) compound

• Cut sections at 4-6 μm thickness for optimal antibody penetration

Antigen retrieval methods:

• Heat-induced epitope retrieval (HIER) with citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Perform retrieval for 20 minutes at 95-100°C

• Allow slides to cool slowly to room temperature

Blocking and antibody incubation:

• Block endogenous peroxidase activity with 3% hydrogen peroxide

• Apply protein block (5% normal serum) for 30 minutes

• Incubate with primary antibody at appropriate dilution (1:100-1:500) overnight at 4°C

• Use appropriate HRP-conjugated secondary antibody for 1 hour at room temperature

Visualization and counterstaining:

• Develop signal with DAB substrate

• Counterstain with hematoxylin

• Mount with permanent mounting medium

Controls to include:

• Positive control: Normal liver tissue (canalicular membrane staining pattern)

• Negative control: Sections incubated with isotype control antibody

• Technical control: Omission of primary antibody

What are the best approaches for studying ABCB4 in cell culture models?

When investigating ABCB4 in cell culture systems, consider these methodological approaches:

Cell line selection:

• Hepatocyte-derived cell lines: HepG2, Huh7, HepaRG

• Polarized epithelial cell lines: MDCK, Caco-2

• Transfected cell lines with stable or inducible ABCB4 expression

Expression systems:

• Plasmid-based transient or stable transfection

• Lentiviral or adenoviral expression systems

• Inducible expression systems (Tet-on/Tet-off)

Functional assays:

• Phosphatidylcholine flippase activity measurement

• ATP hydrolysis assays

• Transport studies using fluorescent phospholipid analogs

• Bile acid toxicity resistance assays

Localization studies:

• Immunofluorescence with co-localization markers for canalicular membrane

• Live-cell imaging with fluorescently-tagged ABCB4

• Cell surface biotinylation for quantification of membrane expression

Protein-protein interaction studies:

• Co-immunoprecipitation with suspected interaction partners

• Proximity ligation assays

• FRET/BRET for direct interaction measurement

How can I distinguish between ABCB4 and the closely related ABCB1 (MDR1/P-glycoprotein) in experimental systems?

Distinguishing between ABCB4 and ABCB1 requires careful methodology due to their structural similarities:

Antibody selection strategy:

• Use antibodies raised against unique epitopes not conserved between ABCB4 and ABCB1

• The P3II-26 clone has been specifically validated for ABCB4 specificity

• Consider using multiple antibodies targeting different epitopes to confirm findings

Expression pattern analysis:

• ABCB4 is predominantly expressed in hepatocytes (canalicular membrane)

• ABCB1 has broader tissue distribution including intestine, kidney, and blood-brain barrier

• Compare staining patterns with known tissue distribution profiles

Functional discrimination:

• ABCB4 primarily transports phosphatidylcholine

• ABCB1 transports a wide range of xenobiotics and drugs

• Design substrate-specific transport assays to differentiate activity

Genetic approaches:

• Use siRNA or CRISPR-Cas9 targeting unique sequences

• Validate knockdown/knockout specificity with primers or antibodies targeting both transporters

• Rescue experiments with construct expressing only one of the transporters

Western blot verification:

• Run paired samples on the same gel

• Probe with antibodies for both proteins

• Look for subtle differences in molecular weight (ABCB4: ~141.5 kDa, ABCB1: ~170 kDa)

What are the best practices for investigating ABCB4 mutations associated with liver diseases?

To study ABCB4 mutations associated with liver disorders such as PFIC3:

Patient sample analysis:

• Obtain appropriate ethical approval and informed consent

• Extract DNA from blood or tissue samples

• Perform targeted sequencing of ABCB4 exons or include in gene panels

• Validate mutations with Sanger sequencing

Functional characterization strategies:

• Generate expression constructs containing wild-type and mutant ABCB4 sequences

• Use site-directed mutagenesis to introduce specific mutations

• Express constructs in polarized cell lines (MDCK II, Caco-2)

• Assess protein localization, stability, and function

Key parameters to measure:

• Protein expression levels by Western blot

• Subcellular localization by immunofluorescence microscopy

• Membrane targeting efficiency

• Phosphatidylcholine flippase activity

• ATP hydrolysis capacity

• Protein half-life/stability

In vivo modeling approaches:

• Generate transgenic mouse models expressing human mutant ABCB4

• Use CRISPR-Cas9 to introduce equivalent mutations in mouse Abcb4

• Analyze liver function, bile composition, and histopathology

• Assess response to therapeutic interventions

Therapeutic screening platforms:

• Test for response to ursodeoxycholic acid and other bile acids

• Screen for compounds that may rescue trafficking defects

• Evaluate chaperone-based approaches for misfolded protein variants

What methodologies are recommended for studying ABCB4 post-translational modifications?

ABCB4 undergoes various post-translational modifications that affect its function and localization. Here are methodological approaches to study these modifications:

Phosphorylation analysis:

• Use phospho-specific antibodies if available

• Perform immunoprecipitation followed by phospho-specific Western blotting

• Utilize mass spectrometry to identify phosphorylation sites

• Test effects of kinase inhibitors on ABCB4 function

• Use phosphomimetic (S/T to D/E) or phospho-dead (S/T to A) mutations to assess functional significance

Glycosylation studies:

• Examine mobility shifts after treatment with glycosidases (PNGase F, Endo H)

• Use lectin blotting to characterize glycan structures

• Mutate potential N-glycosylation sites (N-X-S/T motifs)

• Assess effects of glycosylation inhibitors on trafficking and function

Ubiquitination and degradation pathways:

• Co-immunoprecipitate ABCB4 and probe for ubiquitin

• Use proteasome inhibitors (MG132) or lysosomal inhibitors (bafilomycin A1)

• Perform cycloheximide chase assays to determine protein half-life

• Compare wild-type versus mutant proteins for degradation rates

Palmitoylation and lipid modifications:

• Use acyl-biotin exchange chemistry to detect palmitoylated ABCB4

• Treat with 2-bromopalmitate to inhibit palmitoylation

• Identify potential palmitoylation sites and create cysteine-to-alanine mutants

• Assess membrane localization of wild-type versus modification-deficient mutants

How can I address common challenges in ABCB4 antibody-based experiments?

Researchers often encounter technical difficulties when working with ABCB4 antibodies. Here are solutions to common problems:

Always validate new antibodies using positive control samples (liver tissue) and negative controls (tissues known not to express ABCB4 or ABCB4 knockout samples) .

What validation methods should be employed to confirm ABCB4 antibody specificity?

To ensure ABCB4 antibody specificity, implement these validation strategies:

Positive controls:

• Human liver tissue (especially canalicular membranes of hepatocytes)

• Cells transfected with ABCB4 expression vectors

• Recombinant ABCB4 protein (full-length or fragments)

Negative controls:

• ABCB4 knockout or knockdown systems

• Tissues known not to express ABCB4 (e.g., heart, skeletal muscle)

• Secondary antibody-only controls

Specificity tests:

• Peptide competition/blocking experiments

• Use of multiple antibodies targeting different epitopes

• Correlation of signal with mRNA expression

• Comparison of different application results (WB, IHC, IF)

Advanced validation approaches:

• Immunoprecipitation-mass spectrometry

• Immunohistochemistry on tissue microarrays

• Parallel reaction monitoring of epitope-containing peptides

• Genetic perturbation followed by antibody testing

How should I optimize ABCB4 detection in challenging samples or conditions?

For difficult samples or experimental conditions, consider these optimization strategies:

Low-expressing samples:

• Enrich for membrane proteins using subcellular fractionation

• Use signal amplification systems (tyramide signal amplification)

• Concentrate proteins by immunoprecipitation before Western blot

• Consider more sensitive detection methods (ECL Advance, Clarity Max)

Degradation-prone samples:

• Extract proteins at 4°C with comprehensive protease inhibitor cocktails

• Add additional protease inhibitors specific for membrane proteins

• Avoid freeze-thaw cycles of prepared samples

• Consider fresh samples over frozen when possible

Fixed tissues with potential epitope masking:

• Test multiple antigen retrieval methods (heat, enzyme, pH variations)

• Extend antigen retrieval times

• Try alternative fixatives (zinc-based fixatives instead of formalin)

• Use section thickness appropriate for antibody penetration (4-6 μm)

Specific sample types optimization:

• Frozen tissue: Allow complete fixation in acetone or methanol

• FFPE tissue: Ensure complete deparaffinization and rehydration

• Cell lines: Optimize permeabilization conditions

• Blood samples: Properly isolate mononuclear cells before staining

How can ABCB4 antibodies be utilized in drug development research?

ABCB4 antibodies serve multiple functions in drug development pipelines:

Target validation and expression profiling:

• Quantify ABCB4 expression in various tissues to predict drug effects

• Assess ABCB4 regulation in disease models and patient samples

• Identify patient subpopulations with altered ABCB4 expression

Drug toxicity screening:

• Evaluate drug effects on ABCB4 expression and localization

• Assess potential drug-induced liver injury mechanisms

• Screen compounds for interaction with ABCB4 transport function

Mechanism of action studies:

• Determine if drugs directly interact with ABCB4

• Investigate whether therapeutic effects involve ABCB4 modulation

• Study downstream effects of ABCB4 inhibition or activation

Biomarker development:

• Develop immunoassays for ABCB4 in biological fluids

• Correlate ABCB4 expression with disease progression or drug response

• Use ABCB4 as a predictive biomarker for certain drug toxicities

Therapeutic antibody development:

• Generate antibodies targeting external domains for functional modulation

• Develop antibody-drug conjugates for targeted therapy

• Create diagnostic imaging probes using labeled antibodies

What role does ABCB4 play in precision medicine approaches for liver diseases?

ABCB4 is increasingly important in personalized medicine strategies for hepatobiliary disorders:

Genetic profiling and disease risk:

• Identify patients with ABCB4 mutations or polymorphisms

• Correlate genotypes with clinical phenotypes and disease severity

• Develop genetic screening panels for cholestatic disease risk assessment

Patient stratification strategies:

• Classify patients based on ABCB4 expression/function profiles

• Predict response to ursodeoxycholic acid and other therapies

• Guide treatment selection based on molecular mechanisms

Therapeutic monitoring:

• Track ABCB4 expression changes during treatment

• Correlate with biochemical markers of cholestasis

• Adjust therapy based on molecular response

Novel therapeutic approaches:

• Gene therapy for ABCB4 deficiency

• Pharmacological chaperones for misfolded ABCB4 variants

• Small molecule enhancers of ABCB4 expression or function

Clinical trial design considerations:

• Enrichment strategies based on ABCB4 status

• Molecular endpoints using ABCB4 antibody-based assays

• Companion diagnostic development for targeted therapies

What methodological advances are improving ABCB4 research in complex biological systems?

Recent technological developments enhancing ABCB4 research include:

Advanced imaging techniques:

• Super-resolution microscopy for precise localization studies

• Intravital microscopy to study ABCB4 dynamics in living tissues

• Correlative light and electron microscopy for ultrastructural analysis

• Label-free imaging methods for native protein detection

3D culture and organoid systems:

• Liver organoids for physiologically relevant ABCB4 studies

• Bile duct-on-a-chip models for transport studies

• Co-culture systems modeling hepatocyte-cholangiocyte interactions

• Patient-derived organoids for personalized disease modeling

Single-cell analysis approaches:

• Single-cell RNA-seq to identify ABCB4-expressing cell populations

• Mass cytometry for protein-level quantification in heterogeneous samples

• Spatial transcriptomics to map ABCB4 expression in tissue context

• CyTOF imaging mass cytometry for multiplexed protein detection

In vivo research advancements:

• CRISPR-Cas9 engineered mouse models with human ABCB4 variants

• Humanized liver mouse models for studying human-specific functions

• Non-invasive imaging of ABCB4 function using reporter substrates

• AAV-mediated gene delivery for therapeutic testing

Computational and systems biology integration:

• Molecular dynamics simulations of ABCB4 structure and function

• Machine learning algorithms for predicting mutation effects

• Network analyses of ABCB4 interactions and regulatory pathways

• Virtual screening for ABCB4 modulators